Furthermore, AAV-mediated ACAT1 knockdown has potential therapeutic effects in AD, as delivery of AAV-ACAT1 to the brains of 10-month-old AD mice reduced brain Aβ and human amyloid precursor protein (hAPP) levels at 12 months of age [111]. This evidence concerns the gene ACAT1 and Alzheimer disease.